Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
Zeidner JF, Vincent BG, Ivanova A, Moore D, McKinnon KP, Wilkinson AD, Mukhopadhyay R, Mazziotta F, Knaus HA, Foster MC, Coombs CC, Jamieson K, Van Deventer H, Webster JA, Prince GT, DeZern AE, Smith BD, Levis MJ, Montgomery ND, Luznik L, Serody JS, Gojo I. Zeidner JF, et al. Among authors: gojo i. Blood Cancer Discov. 2021 Sep 10;2(6):616-629. doi: 10.1158/2643-3230.BCD-21-0070. eCollection 2021 Nov. Blood Cancer Discov. 2021. PMID: 34778801 Free PMC article. Clinical Trial.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J. Karp JE, et al. Among authors: gojo i. Blood. 2001 Jun 1;97(11):3361-9. doi: 10.1182/blood.v97.11.3361. Blood. 2001. PMID: 11369625 Free article. Clinical Trial.
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, Chen H, Zwiebel J. Karp JE, et al. Among authors: gojo i. Clin Cancer Res. 2004 Jun 1;10(11):3577-85. doi: 10.1158/1078-0432.CCR-03-0627. Clin Cancer Res. 2004. PMID: 15173063 Clinical Trial.
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS. Karp JE, et al. Among authors: gojo i. Clin Cancer Res. 2005 Dec 1;11(23):8403-12. doi: 10.1158/1078-0432.CCR-05-1201. Clin Cancer Res. 2005. PMID: 16322302 Clinical Trial.
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, Thein M, Sznol M, Low J. Karp JE, et al. Among authors: gojo i. Leuk Res. 2008 Jan;32(1):71-7. doi: 10.1016/j.leukres.2007.05.003. Epub 2007 Jul 20. Leuk Res. 2008. PMID: 17640728 Free PMC article. Clinical Trial.
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K, Redner RL, Arceci R, Owoeye I, Dauses T, Schachter-Tokarz E, Gallagher RE. Gore SD, et al. Among authors: gojo i. J Clin Oncol. 2010 Feb 20;28(6):1047-53. doi: 10.1200/JCO.2009.25.5158. Epub 2010 Jan 19. J Clin Oncol. 2010. PMID: 20085935 Free PMC article. Clinical Trial.
122 results